BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
5 Worldwide Road Food sources You Should Attempt - 2UN chief calls on Yemen's Houthi rebels to free all UN detainees
- 37 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
- 4Treasure trove found in Egyptian tomb solves ancient mystery
- 5A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- The Best 10 Innovation Advancements of the Year
- The Way to Business: Startup Illustrations Learned
- Unwinding the Starting points of America: An Excursion Through History
- 4 DSLR Cameras for Amateurs in 2024
- Some are walking out. Some are shouting. Some are oblivious. How kids are reacting to THAT 'Wicked: For Good' scene
- Couch Styles of 2024: What's Moving
- Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- Going with Children: Tips for Tranquil Family Get-aways
- Cruising Solo All over the Planet: An Excursion of Self-Disclosure
